Dustin Samples

Cancer Nursing Today nonprod

A study at the Huntsman Cancer Institute seeks to determine whether nicotinamide, a form of vitamin B3, can prevent the recurrence of non-melanoma skin cancers (NMSC).Patients with chronic lymphocytic leukemia (CLL) are 7 times more likely to develop recurrent NMSC than patients without CLL who develop NMSC. A phase 3 trial demonstrated that oral nicotinamide reduced recurrent NMSC lesions by 23%, but it excluded patients with histories of other malignancies or immunosuppression.At the 2023 National Comprehensive Cancer Network (NCCN) Annual Meeting, Deborah Stevens, recipient of an NCCN Young Investigator Award, presented a phase 2 trial currently enrolling patients with a history of CLL and NMSC. In the trial, patients will be 1:1 randomized to treatment with nicotinamide or placebo. A dermatologist will examine their skin at 6, 12, 18, and 24 months. At the end of month 12, patients in the placebo group will be switched to the treatment group and continue for 12 months.The total number of lesions will be tallied for both groups at months 12 and 24. The target enrollment of 86 patients (43 per group) will provide sufficient power for statistical analysis. At the time of presentation, the trial had enrolled 11 patients.&ldquo;Planned correlative studies include evaluation of T-cell exhaustion between treatment arms and analysis of B-human papilloma virus (B-HPV) subtypes in CLL cells via whole exome sequencing and skin cancer biopsy samples via polymerase chain reaction,&rdquo; Stevens added.The trial is currently in enrollment at Huntsman Cancer Institute, University of Utah (NCT04844528).<h3>Reference</h3>Stephens DM, Boucher K, Wada DA, et al. Non-melanoma skin cancer (NMSC) in patients with chronic lymphocytic leukemia (CLL): biology and prevention. Presented at the 2023 National Comprehensive Cancer Network Annual Meeting, Orlando, Florida, March 31-April 2, 2003.

Trial for Non-Melanoma Skin Cancer in Patients With CLL Now Enrolling

Conferences

In a currently enrolling trial at the Huntsman Cancer Institute, patients with CLL and NMSC will receive experimental treatment with nicotinamide. 

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe